Limsan, Irene Rose P.
HRN: 05-19-33 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/17/2022
CEFUROXIME 500MG (TAB)
06/17/2022
06/23/2022
PO
500mg
BID X 7 Days
WBC: 23.8; S/p NSVD, Transient Uterine Atony
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes